Mutations of DNAI1 in Primary Ciliary Dyskinesia: Evidence of Founder Effect in a Common Mutation
Primary ciliary dyskinesia (PCD) is a rare, usually autosomal recessive, genetic disorder characterized by ciliary dysfunction, sino-pulmonary disease, and situs inversus. Disease-causing mutations have been reported in DNAI1 and DNAH5 encoding outer dynein arm (ODA) proteins of cilia. We analyzed D...
Saved in:
Published in | American journal of respiratory and critical care medicine Vol. 174; no. 8; pp. 858 - 866 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Am Thoracic Soc
15.10.2006
American Lung Association American Thoracic Society |
Subjects | |
Online Access | Get full text |
ISSN | 1073-449X 1535-4970 |
DOI | 10.1164/rccm.200603-370OC |
Cover
Summary: | Primary ciliary dyskinesia (PCD) is a rare, usually autosomal recessive, genetic disorder characterized by ciliary dysfunction, sino-pulmonary disease, and situs inversus. Disease-causing mutations have been reported in DNAI1 and DNAH5 encoding outer dynein arm (ODA) proteins of cilia.
We analyzed DNAI1 to identify disease-causing mutations in PCD and to determine if the previously reported IVS1+2_3insT (219+3insT) mutation represents a "founder" or "hot spot" mutation.
Patients with PCD from 179 unrelated families were studied. Exclusion mapping showed no linkage to DNAI1 for 13 families; the entire coding region was sequenced in a patient from the remaining 166 families. Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed on nasal epithelial RNA in 14 families.
Mutations in DNAI1 including 12 novel mutations were identified in 16 of 179 (9%) families; 14 harbored biallelic mutations. Deep intronic splice mutations were not identified by reverse transcriptase-polymerase chain reaction. The prevalence of mutations in families with defined ODA defect was 13%; no mutations were found in patients without a defined ODA defect. The previously reported IVS1+2_3insT mutation accounted for 57% (17/30) of mutant alleles, and marker analysis indicates a common founder for this mutation. Seven mutations occurred in three exons (13, 16, and 17); taken together with previous reports, these three exons are emerging as mutation clusters harboring 29% (12/42) of mutant alleles.
A total of 10% of patients with PCD are estimated to harbor mutations in DNAI1; most occur as a common founder IVS1+2_3insT or in exons 13, 16, and 17. This information is useful for establishing a clinical molecular genetic test for PCD. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 PMCID: PMC2648054 Supported by grants GCRC 00046, MO1 RR00046-42, 1 RO1 HL071798, Deutsch Forschungsgemeinschaft (SFB592 and DFG Om6/2), GIS Maladies Rares A03091, the ANR Maladies Rares, the Assistance Publique-Hôpitaux de Paris (CRC 96125), Concord Hospital, the Medical Research Council (UK), the Milena Carvajal Pro-Kartagener Foundation, the Wellcome Trust (UK), and grant 5 U54 RR019480 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org Conflict of Interest Statement: M.A.Z. is a coinvestigator on a research grant from the North Carolina Technology Center to develop assays relating to DNAI1. The grant amount is $250,000 for the total of 2 yr (June 1, 2006 through May 31, 2008). No work in the current study was supported by this grant. M.W.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. F.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.P.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. P.G.N. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.L.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.J.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. H.O. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. N.T.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.-M.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. H.M.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.M.K.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. L.M.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.U.d.I. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. U.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. H.O. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.R.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Correspondence and requests for reprints should be addressed to Maimoona Zariwala, Ph.D., F.A.C.M.G., The University of North Carolina at Chapel Hill, Department of Pathology and Laboratory Medicine, CB# 7248, 7123 Thurston-Bowles Bldg., Chapel Hill, NC 27599-7248. E-mail: zariwala@med.unc.edu Originally Published in Press as DOI: 10.1164/rccm.200603-370OC on August 3, 2006 |
ISSN: | 1073-449X 1535-4970 |
DOI: | 10.1164/rccm.200603-370OC |